BioSpace News Archive

U.S. Food and Drug Administration Approves Opdivo ® (nivolumab) + Yervoy ® (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma Opdivo + Yervoy is the first new systemic therapy in over 15 years to be approved by the FDA in this setting 1,2 Approval is based on CheckMate -743 in which Opdivo + Yervoy demonstrated superior overall survival vs. standard of care chemot

Select Medical Holdings Corporation (“Select Medical”) (NYSE: SEM), will release the financial results for its third quarter ended September 30, 2020 on Thursday, October 29, 2020 after the market closes.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on October 1, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 12,375 shares of Puma common stock to 2 new non-executive employees.

Presentations to include follow-up MINDACT study data and evaluations on the use of MammaPrint to guide treatment decisions in lobular cancers and for screen-detected breast cancers versus interval-detected breast cancers IRVINE, Calif. , Oct. 2, 2020 /PRNewswire/ -- Agendia, Inc., a world leader in precision oncology for breast cancer, today announced the presentation o

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, announced it has entered into a definitive agreement to merge with purification specialist BIA Separations in a transaction totaling 360 million euros of which 240 million euros will be paid in cash and 120 million euros in Sartorius Stedim Biotech shares.

Passion and Dedication of Myeloma Patients and Caregivers Contribute to Advancing Awareness and Raising Funds for Incurable Blood Cancer.

Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announces that, further to its September 25, 2020 press release , it today has filed its interim financial statements and related MD&A for the three months ended July 31, 2020 (the “Interim Filings”). These filings can be found at www.sedar.com under the Company’s profile . About Resverlogix Resverlogix is developing apabetalone (RVX-208), a first-in-class, small mole

The Pivot Breath Sensor was evaluated in a clinical trial involving 234 people who smoke cigarettes to determine its effects on smoking behavior and attitudes

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to market its Sofia® 2 Flu + SARS Antigen FIA,

Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its NexSys PCS® system with Persona™ technology.